Asset Details
Do you wish to reserve the book?
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Do you wish to request the book?
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
2021
Overview
A subset of breast cancer patients benefits from preoperative bevacizumab and chemotherapy, but validated predictive biomarkers are lacking. Here, we aimed to evaluate tissue-based angiogenesis markers for potential predictive value regarding response to neoadjuvant bevacizumab treatment in breast cancer. In this randomized 1:1 phase II clinical trial, 132 patients with large or locally advanced HER2-negative tumors received chemotherapy ± bevacizumab. Dual Factor VIII/Ki-67 immunohistochemical staining was performed on core needle biopsies at baseline and week 12. Microvessel density (MVD), proliferative microvessel density (pMVD; Factor VIII/Ki-67 co-expression), glomeruloid microvascular proliferation (GMP), and a gene expression angiogenesis signature score, were studied in relation to pathologic complete response (pCR), clinico-pathologic features and intrinsic molecular subtype. We found that high baseline MVD (by median) significantly predicted pCR in the bevacizumab-arm (odds ratio 4.9,
P
= 0.012). High pMVD, presence of GMP, and the angiogenesis signature score did not predict pCR, but were associated with basal-like (
P
≤ 0.009) and triple negative phenotypes (
P
≤ 0.041). pMVD and GMP did also associate with high-grade tumors (
P
≤ 0.048). To conclude, high baseline MVD significantly predicted response to bevacizumab treatment. In contrast, pMVD, GMP, and the angiogenesis signature score, did not predict response, but associated with aggressive tumor features, including basal-like and triple-negative phenotypes.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Adult
/ Aged
/ Bevacizumab - administration & dosage
/ Breast Neoplasms - blood supply
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - pathology
/ Female
/ Humanities and Social Sciences
/ Humans
/ Neovascularization, Pathologic - drug therapy
/ Neovascularization, Pathologic - pathology
/ Patients
/ Science
/ Tumors
